JP2015500328A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015500328A5 JP2015500328A5 JP2014546670A JP2014546670A JP2015500328A5 JP 2015500328 A5 JP2015500328 A5 JP 2015500328A5 JP 2014546670 A JP2014546670 A JP 2014546670A JP 2014546670 A JP2014546670 A JP 2014546670A JP 2015500328 A5 JP2015500328 A5 JP 2015500328A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- tumor
- brain
- minicells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002246 antineoplastic agent Substances 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 15
- 229940034982 antineoplastic agent Drugs 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 11
- 102000039446 nucleic acids Human genes 0.000 claims description 11
- 150000007523 nucleic acids Chemical class 0.000 claims description 11
- 229940127089 cytotoxic agent Drugs 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 230000006907 apoptotic process Effects 0.000 claims description 5
- 108091033319 polynucleotide Proteins 0.000 claims description 5
- 102000040430 polynucleotide Human genes 0.000 claims description 5
- 239000002157 polynucleotide Substances 0.000 claims description 5
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 239000002158 endotoxin Substances 0.000 claims description 4
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 210000004027 cell Anatomy 0.000 claims description 3
- 230000025084 cell cycle arrest Effects 0.000 claims description 3
- 238000002512 chemotherapy Methods 0.000 claims description 3
- PNDPGZBMCMUPRI-HVTJNCQCSA-N 10043-66-0 Chemical compound [131I][131I] PNDPGZBMCMUPRI-HVTJNCQCSA-N 0.000 claims description 2
- 108020005544 Antisense RNA Proteins 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 claims description 2
- 108090000994 Catalytic RNA Proteins 0.000 claims description 2
- 102000053642 Catalytic RNA Human genes 0.000 claims description 2
- GYHNNYVSQQEPJS-OIOBTWANSA-N Gallium-67 Chemical compound [67Ga] GYHNNYVSQQEPJS-OIOBTWANSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-AHCXROLUSA-N Iodine-123 Chemical compound [123I] ZCYVEMRRCGMTRW-AHCXROLUSA-N 0.000 claims description 2
- 108091007460 Long intergenic noncoding RNA Proteins 0.000 claims description 2
- IGLNJRXAVVLDKE-OIOBTWANSA-N Rubidium-82 Chemical compound [82Rb] IGLNJRXAVVLDKE-OIOBTWANSA-N 0.000 claims description 2
- 108091027967 Small hairpin RNA Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- GKLVYJBZJHMRIY-OUBTZVSYSA-N Technetium-99 Chemical compound [99Tc] GKLVYJBZJHMRIY-OUBTZVSYSA-N 0.000 claims description 2
- FHNFHKCVQCLJFQ-NJFSPNSNSA-N Xenon-133 Chemical compound [133Xe] FHNFHKCVQCLJFQ-NJFSPNSNSA-N 0.000 claims description 2
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical group [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims description 2
- 239000003184 complementary RNA Substances 0.000 claims description 2
- YCKRFDGAMUMZLT-BJUDXGSMSA-N fluorine-18 atom Chemical compound [18F] YCKRFDGAMUMZLT-BJUDXGSMSA-N 0.000 claims description 2
- 229940006110 gallium-67 Drugs 0.000 claims description 2
- 229940055742 indium-111 Drugs 0.000 claims description 2
- APFVFJFRJDLVQX-AHCXROLUSA-N indium-111 Chemical compound [111In] APFVFJFRJDLVQX-AHCXROLUSA-N 0.000 claims description 2
- 108091070501 miRNA Proteins 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108091092562 ribozyme Proteins 0.000 claims description 2
- 239000002924 silencing RNA Substances 0.000 claims description 2
- 239000004055 small Interfering RNA Substances 0.000 claims description 2
- 229940056501 technetium 99m Drugs 0.000 claims description 2
- BKVIYDNLLOSFOA-OIOBTWANSA-N thallium-201 Chemical compound [201Tl] BKVIYDNLLOSFOA-OIOBTWANSA-N 0.000 claims description 2
- 229940106670 xenon-133 Drugs 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 208000003174 Brain Neoplasms Diseases 0.000 claims 13
- 230000033115 angiogenesis Effects 0.000 claims 6
- 210000004881 tumor cell Anatomy 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 208000005017 glioblastoma Diseases 0.000 claims 3
- 208000003200 Adenoma Diseases 0.000 claims 2
- 206010001233 Adenoma benign Diseases 0.000 claims 2
- 206010003571 Astrocytoma Diseases 0.000 claims 2
- 208000009798 Craniopharyngioma Diseases 0.000 claims 2
- 206010014967 Ependymoma Diseases 0.000 claims 2
- 206010025323 Lymphomas Diseases 0.000 claims 2
- 201000010133 Oligodendroglioma Diseases 0.000 claims 2
- 206010057249 Phagocytosis Diseases 0.000 claims 2
- 210000004204 blood vessel Anatomy 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 210000004962 mammalian cell Anatomy 0.000 claims 2
- 230000001394 metastastic effect Effects 0.000 claims 2
- 206010061289 metastatic neoplasm Diseases 0.000 claims 2
- 230000008782 phagocytosis Effects 0.000 claims 2
- 230000001817 pituitary effect Effects 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108010001857 Cell Surface Receptors Proteins 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 102000006240 membrane receptors Human genes 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 241001474374 Blennius Species 0.000 description 1
- 235000014653 Carica parviflora Nutrition 0.000 description 1
- 241000243321 Cnidaria Species 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161569907P | 2011-12-13 | 2011-12-13 | |
| US61/569,907 | 2011-12-13 | ||
| PCT/IB2012/002950 WO2013088250A1 (en) | 2011-12-13 | 2012-12-12 | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017158959A Division JP6594383B2 (ja) | 2011-12-13 | 2017-08-22 | 治療薬を脳腫瘍に送達するための細菌由来のインタクトなミニセル |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015500328A JP2015500328A (ja) | 2015-01-05 |
| JP2015500328A5 true JP2015500328A5 (cg-RX-API-DMAC7.html) | 2016-02-04 |
| JP6522340B2 JP6522340B2 (ja) | 2019-05-29 |
Family
ID=48611925
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546670A Active JP6522340B2 (ja) | 2011-12-13 | 2012-12-12 | 治療薬を脳腫瘍に送達するための細菌由来のインタクトなミニセル |
| JP2017158959A Active JP6594383B2 (ja) | 2011-12-13 | 2017-08-22 | 治療薬を脳腫瘍に送達するための細菌由来のインタクトなミニセル |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017158959A Active JP6594383B2 (ja) | 2011-12-13 | 2017-08-22 | 治療薬を脳腫瘍に送達するための細菌由来のインタクトなミニセル |
Country Status (23)
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA05007322A (es) * | 2003-01-06 | 2006-02-17 | Angiochem Inc | Aprotinina y analogos como portadores a traves de la barrera sangre-cerebro. |
| US9365634B2 (en) * | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
| MX355683B (es) | 2008-04-18 | 2018-04-26 | Angiochem Inc | Composiciones farmacéuticas de paclitaxel, análogos de paclitaxel o conjugados de paclitaxel, y métodos relacionados de preparación y uso. |
| CA2740316A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of glp-1 agonists and uses thereof |
| CN102245636A (zh) | 2008-10-15 | 2011-11-16 | 安吉奥开米公司 | 用于药物递送的依托泊苷和多柔比星结合物 |
| MX2011005963A (es) | 2008-12-05 | 2011-09-01 | Angiochem Inc | Conjugados de neurotensina o analogos de neurotensina y sus usos. |
| EP2373789A4 (en) | 2008-12-17 | 2012-08-29 | Angiochem Inc | MEMBRANTYP-1 MATRIX METALLOPROTEINASE INHIBITORS AND THEIR USE |
| BRPI1015295A2 (pt) | 2009-04-20 | 2016-05-31 | Angiochem Inc | traamento de câncer de ovário usando um agente anticâncer conjugado a um análogo angiopep-2. |
| RU2012103240A (ru) | 2009-07-02 | 2013-08-10 | Ангиокем Инк. | Мультимерные пептидные конъюгаты и их применение |
| EP2600901B1 (en) | 2010-08-06 | 2019-03-27 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
| MX2013003681A (es) | 2010-10-01 | 2013-11-20 | Moderna Therapeutics Inc | Ácidos nucleicos manipulados y métodos de uso de los mismos. |
| WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| US9428535B2 (en) | 2011-10-03 | 2016-08-30 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| ES2843402T3 (es) | 2011-12-13 | 2021-07-16 | Engeneic Molecular Delivery Pty Ltd | Minicélulas intactas de origen bacteriano para la administración de agentes terapéuticos a tumores cerebrales |
| SMT202200355T1 (it) | 2011-12-16 | 2022-11-18 | Modernatx Inc | Composizioni di mrna modificato |
| EP2834260A4 (en) | 2012-04-02 | 2016-08-10 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PREPARATION OF MEMBRANE PROTEINS |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US10501512B2 (en) | 2012-04-02 | 2019-12-10 | Modernatx, Inc. | Modified polynucleotides |
| EP2922554B1 (en) | 2012-11-26 | 2022-02-23 | ModernaTX, Inc. | Terminally modified rna |
| EP2971010B1 (en) | 2013-03-14 | 2020-06-10 | ModernaTX, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| CA2923029A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3041938A1 (en) | 2013-09-03 | 2016-07-13 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
| JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
| CN105658233B (zh) * | 2013-10-04 | 2020-09-04 | 安吉尼科分子传输公司 | 使用携带药物的、双特异性配体靶向的微细胞和干扰素-γ的联合肿瘤治疗 |
| CA2955177A1 (en) * | 2014-07-15 | 2016-01-21 | The Johns Hopkins University | Suppression of myeloid derived suppressor cells and immune checkpoint blockade |
| US20170204152A1 (en) | 2014-07-16 | 2017-07-20 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| EP3171895A1 (en) | 2014-07-23 | 2017-05-31 | Modernatx, Inc. | Modified polynucleotides for the production of intrabodies |
| US10328159B2 (en) | 2014-10-03 | 2019-06-25 | Engenic Molecular Delivery Pty Ltd. | Enhanced loading of intact, bacterially derived vesicles with small molecule compounds |
| DK3307326T3 (da) | 2015-06-15 | 2020-10-19 | Angiochem Inc | Fremgangsmåder til behandling af leptomeningeal karcinomatose |
| LT3394093T (lt) | 2015-12-23 | 2022-04-25 | Modernatx, Inc. | Ox40 ligandus koduojančių polinukleotidų naudojimo būdai |
| WO2017120612A1 (en) | 2016-01-10 | 2017-07-13 | Modernatx, Inc. | Therapeutic mrnas encoding anti ctla-4 antibodies |
| AU2018270111B2 (en) | 2017-05-18 | 2022-07-14 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| CA3095134A1 (en) | 2018-03-28 | 2019-10-03 | Board Of Regents, The University Of Texas System | Identification of epigenetic alterations in dna isolated from exosomes |
| DE102018220892A1 (de) * | 2018-12-04 | 2020-06-04 | Robert Bosch Gmbh | Vorrichtung und Verfahren zur Generierung von Labelobjekten für die Umgebung eines Fahrzeugs |
| PH12021551315A1 (en) * | 2018-12-10 | 2022-05-16 | Flagship Pioneering Innovations Vi Llc | Achromosomal dynamic active systems |
| WO2020222161A1 (en) * | 2019-05-01 | 2020-11-05 | Engeneic Molecular Delivery Pty Ltd | Compositions comprising bacterially derived intact minicells for theranostic applications |
| JP2022536982A (ja) * | 2019-06-21 | 2022-08-22 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 癌およびその他の疾患の処置のためのα３β１インテグリンの標的化 |
| CN111001014B (zh) * | 2019-12-12 | 2022-04-22 | 四川大学华西医院 | 一种基于固定细菌做载体的抗肿瘤药物及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0222340Y2 (cg-RX-API-DMAC7.html) | 1986-11-18 | 1990-06-15 | ||
| US6962702B2 (en) | 1998-06-22 | 2005-11-08 | Immunomedics Inc. | Production and use of novel peptide-based agents for use with bi-specific antibodies |
| US6540980B1 (en) | 1999-04-02 | 2003-04-01 | Center For Molecular Medicine And Immunology | Method of detecting endometriosis |
| CN1308347C (zh) | 1999-04-28 | 2007-04-04 | 德克萨斯大学董事会 | 用于通过选择性抑制vegf来治疗癌症的组合物和方法 |
| FR2793684B1 (fr) | 1999-05-17 | 2001-08-10 | Ethypharm Lab Prod Ethiques | Utilisation de microspheres biodegradables liberant un agent anticancereux pour le traitement du glioblastome, procede de preparation de ces microspheres et suspension les contenant |
| US20030194798A1 (en) * | 2001-05-24 | 2003-10-16 | Surber Mark W. | Minicell compositions and methods |
| US20030203411A1 (en) * | 2001-06-05 | 2003-10-30 | Sabbadini Roger A. | Methods of minicell-based delivery |
| CA2775218C (en) * | 2001-10-15 | 2016-04-26 | Engeneic Molecular Delivery Pty Ltd. | Intact minicells as vectors for dna transfer and gene therapy in vitro and in vivo |
| US7332585B2 (en) * | 2002-04-05 | 2008-02-19 | The Regents Of The California University | Bispecific single chain Fv antibody molecules and methods of use thereof |
| US20040005700A1 (en) * | 2002-05-28 | 2004-01-08 | Surber Mark W. | Poroplasts |
| ATE461713T1 (de) | 2002-05-29 | 2010-04-15 | Immunomedics Inc | Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren |
| KR101115797B1 (ko) * | 2002-08-01 | 2012-07-27 | 이뮤노메딕스, 인코오포레이티드 | 알파 태아 단백질 Ｉｍｍｕ31 항체 및 융합단백질, 및이들의 이용 방법 |
| US7611885B2 (en) * | 2003-06-24 | 2009-11-03 | Engeneic Molecular Delivery Pty, Ltd. | Pharmaceutically compatible method for purifying intact bacterial minicells |
| CN101954095B (zh) * | 2003-12-09 | 2013-03-13 | 基因分子传递股份有限公司 | 通过源自细菌的完整小细胞将靶基因递送至非吞噬哺乳动物细胞 |
| RS54149B1 (sr) * | 2004-02-02 | 2015-12-31 | Engeneic Molecular Delivery Pty Ltd. | Kompozicije i postupci in vitro i in vivo, ciljanog oslobađanja leka u ćelijama sisara, preko intaktnih minićelija izvedenih iz bakterija |
| US8772013B2 (en) * | 2004-02-02 | 2014-07-08 | Engeneic Molecular Delivery Pty Ltd | Methods for targeted in vitro and in vivo drug delivery to mammalian cells via bacterially derived intact minicells |
| US7837998B2 (en) * | 2004-05-21 | 2010-11-23 | Nathaniel Lallatin | Anti-cancer activity of an anti-thymidine kinase monoclonal antibody |
| MX2007002294A (es) * | 2004-08-26 | 2007-10-19 | Engeneic Molecular Delivery Pty Ltd | Suministro de acidos nucleicos funcionales a celulas mamiferas via minicelulas intactas, derivadas bacterialmente. |
| WO2006099445A2 (en) | 2005-03-14 | 2006-09-21 | Massachusetts Institute Of Technology | Nanocells for diagnosis and treatment of diseases and disorders |
| JP2009531324A (ja) * | 2006-03-20 | 2009-09-03 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 癌標的化のための操作された抗前立腺幹細胞抗原（ｐｓｃａ）抗体 |
| PL2712618T3 (pl) * | 2006-06-23 | 2017-07-31 | Engeneic Molecular Delivery Pty Ltd. | Ukierunkowane dostarczanie leków, terapeutycznych kwasów nukleinowych i funkcjonalnych kwasów nukleinowych do komórek ssaczych przez nienaruszone, uśmiercone komórki bakteryjne |
| WO2008050255A2 (en) | 2006-10-25 | 2008-05-02 | Koninklijke Philips Electronics N. V. | Contrast agents for detecting prostate cancer |
| SG10201507969PA (en) | 2007-03-30 | 2015-10-29 | Engeneic Molecular Delivery Pty Ltd | Bacterially-derived, intact minicells that encompass plasmid-free functional nucleic acid for in vivo delivery to mammalian cells |
| EP3020811A1 (en) * | 2008-06-25 | 2016-05-18 | Vaxiion Therapeutics, LLC | Regulated genetic suicide mechanism compositions and methods |
| EP3059247B1 (en) * | 2008-12-05 | 2017-09-20 | Abraxis BioScience, LLC | Sparc binding peptides and uses thereof |
| JP6040148B2 (ja) | 2010-04-20 | 2016-12-07 | ゲンマブ エー／エス | ヘテロ二量体抗体Ｆｃ含有タンパク質およびその産生方法 |
| DK2675474T3 (en) * | 2011-02-15 | 2019-04-23 | Vaxiion Therapeutics Llc | THERAPEUTIC COMPOSITIONS AND PROCEDURES FOR TARGETED ADMINISTRATION OF BIOACTIVE MOLECULES BY BACK-TERIAL MINICLES BASED ON ANTIBODY AND FC-CONTAINING TAR-GETING MOLECULES |
| ES2843402T3 (es) | 2011-12-13 | 2021-07-16 | Engeneic Molecular Delivery Pty Ltd | Minicélulas intactas de origen bacteriano para la administración de agentes terapéuticos a tumores cerebrales |
| EP3826654A4 (en) | 2018-07-23 | 2022-07-06 | EnGeneIC Molecular Delivery Pty Ltd | COMPOSITIONS COMPRISING MINICELLS OF BACTERIAL ORIGIN AND THEIR METHODS OF USE |
-
2012
- 2012-12-12 ES ES12857452T patent/ES2843402T3/es active Active
- 2012-12-12 DK DK12857452.2T patent/DK2790668T3/da active
- 2012-12-12 RS RS20201489A patent/RS61161B1/sr unknown
- 2012-12-12 MX MX2014006967A patent/MX359410B/es active IP Right Grant
- 2012-12-12 US US13/711,848 patent/US9844598B2/en active Active
- 2012-12-12 KR KR1020147019228A patent/KR20140102294A/ko not_active Ceased
- 2012-12-12 LT LTEP12857452.2T patent/LT2790668T/lt unknown
- 2012-12-12 KR KR1020197019600A patent/KR102046042B1/ko active Active
- 2012-12-12 AU AU2012351743A patent/AU2012351743B2/en active Active
- 2012-12-12 HU HUE12857452A patent/HUE052136T2/hu unknown
- 2012-12-12 CA CA2858315A patent/CA2858315C/en active Active
- 2012-12-12 EP EP12857452.2A patent/EP2790668B1/en active Active
- 2012-12-12 PT PT128574522T patent/PT2790668T/pt unknown
- 2012-12-12 HR HRP20201930TT patent/HRP20201930T1/hr unknown
- 2012-12-12 WO PCT/IB2012/002950 patent/WO2013088250A1/en not_active Ceased
- 2012-12-12 MX MX2018011664A patent/MX385832B/es unknown
- 2012-12-12 CN CN201280069592.1A patent/CN104114153A/zh active Pending
- 2012-12-12 RU RU2014128338A patent/RU2664698C2/ru active
- 2012-12-12 JP JP2014546670A patent/JP6522340B2/ja active Active
- 2012-12-12 CN CN201811227385.XA patent/CN109125286A/zh active Pending
- 2012-12-12 SG SG10201601349XA patent/SG10201601349XA/en unknown
- 2012-12-12 SM SM20200676T patent/SMT202000676T1/it unknown
- 2012-12-12 SG SG11201403062YA patent/SG11201403062YA/en unknown
- 2012-12-12 SI SI201231862T patent/SI2790668T1/sl unknown
- 2012-12-13 TW TW101147186A patent/TWI627966B/zh active
-
2014
- 2014-06-09 IL IL233031A patent/IL233031B/en active IP Right Grant
-
2017
- 2017-08-22 JP JP2017158959A patent/JP6594383B2/ja active Active
- 2017-10-05 AU AU2017239542A patent/AU2017239542B2/en active Active
- 2017-10-23 US US15/790,885 patent/US10994014B2/en active Active
-
2020
- 2020-11-13 CY CY20201101075T patent/CY1123824T1/el unknown
-
2021
- 2021-03-25 US US17/212,995 patent/US11964021B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015500328A5 (cg-RX-API-DMAC7.html) | ||
| Mirzaei et al. | Diagnostic and therapeutic potential of exosomes in cancer: the beginning of a new tale? | |
| Kim et al. | In vivo visualization of endogenous miR-21 using hyaluronic acid-coated graphene oxide for targeted cancer therapy | |
| WO2013088250A4 (en) | Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors | |
| ES2649165T3 (es) | CD47 terapias dirigidas para el tratamiento de enfermedades infecciosas | |
| ES3046884T3 (en) | Use of aptamers in therapy and/or diagnosis of autoimmune diseases | |
| JP2017506074A5 (cg-RX-API-DMAC7.html) | ||
| Pereira et al. | Aptamers: Novelty tools for cancer biology | |
| Scaggiante et al. | Aptamers as targeting delivery devices or anti-cancer drugs for fighting tumors | |
| SI2929031T1 (en) | PCSK9 IRNA assemblies and procedures for their use | |
| RU2015119409A (ru) | Конъюгаты олигонуклеотидов | |
| JP2019527563A5 (cg-RX-API-DMAC7.html) | ||
| JP2015513919A5 (cg-RX-API-DMAC7.html) | ||
| Doherty et al. | Aptamers in neuro-oncology: an emerging therapeutic modality | |
| US20200208157A1 (en) | Rna ligand-displaying exosomes for specific delivery of therapeutics to cell by rna nanotechnology | |
| Park et al. | Hybridization-based aptamer labeling using complementary oligonucleotide platform for PET and optical imaging | |
| JP2016539623A5 (cg-RX-API-DMAC7.html) | ||
| Ghasemi et al. | Tumor-derived microvesicles: the metastasomes | |
| JP2015096073A (ja) | 阻害性オリゴヌクレオチドを送達するための組成物および方法 | |
| Dai et al. | Pancreatic cancer: Nucleic acid drug discovery and targeted therapy | |
| Lian et al. | Positive feedback loop of hepatoma-derived growth factor and β-catenin promotes carcinogenesis of colorectal cancer | |
| Li et al. | Selection of CD133-targeted DNA aptamers for the efficient and specific therapy of colorectal cancer | |
| Rotoli et al. | Advances in oligonucleotide aptamers for NSCLC targeting | |
| Jiang et al. | Engineered exosomes in service of tumor immunotherapy: From optimizing tumor‐derived exosomes to delivering CRISPR/Cas9 system | |
| Zhong et al. | Advances of aptamer-based clinical applications for the diagnosis and therapy of cancer |